New drug cocktail aims to tackle tough blood cancers
NCT ID NCT07520006
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called NX-5948 (bexobrutideg) combined with other medicines (venetoclax, and possibly rituximab or obinutuzumab) in adults with B-cell lymphoma, chronic lymphocytic leukemia, or small lymphocytic lymphoma. The goal is to see if the combination is safe and effective for people whose cancer has returned or not responded to prior treatments, as well as for those receiving first-time therapy. About 150 participants will take part across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NX-5948 (bexobrutideg) combined with venetoclax and possibly rituximab or obinutuzumab
- What this could lead to
- If successful, this could offer a new combination treatment option for people with certain blood cancers that have stopped responding to standard therapy.
- What could go wrong
- This is an early-phase trial (1b/2) with a small number of participants, so results may not apply broadly. Side effects from the drug combinations are possible and not yet fully known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can antibody infusions outperform antibiotics in shielding CAR-T patients from infections?
- Can a Three-Drug combo outsmart High-Risk CLL?
- Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?
- Can a Two-Drug combo wipe out hidden leukemia cells?